{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:08:05Z","timestamp":1785557285396,"version":"3.56.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Padjadjaran"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemotherapy is integral to many curative-intent regimens for HER2-positive breast cancer, but it contributes substantial toxicity and treatment burden, motivating interest in de-escalation strategies paired with HER2-targeted therapy. We conducted a systematic review and meta-analysis to quantify comparative effectiveness and safety of chemotherapy de-escalation approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, EMBASE, and Scopus were searched from inception to December 16, 2025 for English, peer-reviewed adult human randomized controlled trials (RCTs), cohort, or case\u2013control studies evaluating chemotherapy omission, reduction, substitution, or shortening versus a contemporaneous comparator. Study selection, data extraction, and risk-of-bias assessment (Cochrane Risk of Bias 2 for RCTs; ROBINS-I for non-randomized studies) were performed by all authors with discrepancies resolved by discussion. Random-effects meta-analyses were performed in RevMan 5.4 using risk ratios (RR) for pCR, odds ratios (OR) for serious adverse events, and hazard ratios (HR) for time-to-event outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six studies (total\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20091,770) met inclusion criteria, largely in operable early to locally advanced settings with varied de-escalation backbones. Pooled estimates showed no clear differences in disease-free survival (HR 0.97, 95% CI 0.45\u20132.12;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.95; I\u00b2=64%), recurrence-free survival (HR 0.85, 95% CI 0.30\u20132.39;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.76; I\u00b2=75%), or pCR (RR 0.53, 95% CI 0.13\u20132.21;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.19; I\u00b2=90%), while serious adverse events were reduced (OR 0.37, 95% CI 0.15\u20130.88;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03; I\u00b2=62%). The pooled overall survival estimate (HR 0.98, 95% CI 0.96\u20130.99;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004) was driven predominantly by a single large-sample study and should be interpreted with caution given sparse event counts and the exploratory nature of survival endpoints in most included trials.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Chemotherapy de-escalation may reduce severe toxicity in selected patients with HER2-positive early breast cancer, but heterogeneity in de-escalation strategies, study designs, and outcome definitions and imprecision limit definitive inference. Most included trials were not powered for long-term survival endpoints, and pooled survival estimates should be regarded as hypothesis-generating rather than practice-defining. Adequately powered, randomized trials with prespecified non-inferiority margins and standardized endpoints are needed to establish the safety and efficacy of specific de-escalation approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16149-1","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:45:35Z","timestamp":1778733935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["De-escalation of chemotherapy in HER2-positive breast cancer management: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3502-8519","authenticated-orcid":false,"given":"Gideon","family":"Setiawan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2148-0202","authenticated-orcid":false,"given":"Yohana","family":"Azhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1233-5601","authenticated-orcid":false,"given":"Maman","family":"Abdurahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0275-5488","authenticated-orcid":false,"given":"Monty Priosodewo","family":"Soemitro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2940-5170","authenticated-orcid":false,"given":"Kiki A.","family":"Rizky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"16149_CR1","doi-asserted-by":"publisher","first-page":"598","DOI":"10.29303\/jbt.v25i4a.10991","volume":"25","author":"MF Adidaifa","year":"2025","unstructured":"Adidaifa MF, Literature Review. JBT. 2025;25:598\u2013604. https:\/\/doi.org\/10.29303\/jbt.v25i4a.10991.","journal-title":"JBT"},{"key":"16149_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s42399-025-02195-6","volume":"7","author":"M Savitri","year":"2025","unstructured":"Savitri M, Sutanto H, Romadhon PZ, et al. Quality of Life Following Breast Cancer Chemotherapy: A Narrative Review of Patient-Reported Outcomes and Supportive Care. SN Compr Clin Med. 2025;7:432.","journal-title":"SN Compr Clin Med"},{"key":"16149_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00520-025-09664-7","volume":"33","author":"AE Smith","year":"2025","unstructured":"Smith AE, Harrison M, McNeil C, et al. Assessment of long-term alopecia after adjuvant taxane therapy for early breast cancer: a cross-sectional survey. Support Care Cancer. 2025;33:615.","journal-title":"Support Care Cancer"},{"key":"16149_CR4","doi-asserted-by":"crossref","unstructured":"Li X, Huang T. Advances in the intrinsic signaling pathway interactions and clinical translation of HR+\/HER2\u2009+\u2009breast cancer. Breast Cancer. 2025;32(6):1216\u201343.","DOI":"10.1007\/s12282-025-01779-3"},{"key":"16149_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3390\/cancers14030512","volume":"14","author":"C Bueno Mui\u00f1o","year":"2022","unstructured":"Bueno Mui\u00f1o C, Mart\u00edn M, Del Monte-Mill\u00e1n M, et al. HER2\u2009+\u2009Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping. Cancers (Basel). 2022;14:512.","journal-title":"Cancers (Basel)"},{"key":"16149_CR6","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"16149_CR7","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"16149_CR8","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"16149_CR9","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1200\/JCO.23.02170","volume":"42","author":"P Tarantino","year":"2024","unstructured":"Tarantino P, Tayob N, Villacampa G, et al. Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. J Clin Oncol. 2024;42:3652\u201365.","journal-title":"J Clin Oncol"},{"key":"16149_CR10","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","volume":"403","author":"JM P\u00e9rez-Garc\u00eda","year":"2024","unstructured":"P\u00e9rez-Garc\u00eda JM, Cort\u00e9s J, Ruiz-Borrego M, et al. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet. 2024;403:1649\u201359.","journal-title":"Lancet"},{"key":"16149_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(22)00159-0","volume":"23","author":"U Nitz","year":"2022","unstructured":"Nitz U, Gluz O, Graeser M, et al. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+\/HR-): survival outcomes. Lancet Oncol. 2022;23:625\u201335.","journal-title":"Lancet Oncol"},{"key":"16149_CR12","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jamaoncol.2021.1932","volume":"7","author":"T Hatschek","year":"2021","unstructured":"Hatschek T, Foukakis T, Bj\u00f6hle J, et al. Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7:1360\u20137.","journal-title":"JAMA Oncol"},{"key":"16149_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25\u201332.","journal-title":"Lancet Oncol"},{"key":"16149_CR14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.clbc.2023.01.013","volume":"23","author":"S Bari","year":"2023","unstructured":"Bari S, Li J, Kang D, et al. A Real-World Data Retrospective Cohort Study of HER2-positive, Early-Stage Breast Cancer in Patients 70 Years of Age or Older: Natural History, Treatment Patterns, and Outcomes. Clin Breast Cancer. 2023;23:378\u201387.","journal-title":"Clin Breast Cancer"},{"key":"16149_CR15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","volume":"14","author":"SM Swain","year":"2013","unstructured":"Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14:461\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(13)70130-X.","journal-title":"Lancet Oncol"},{"key":"16149_CR16","doi-asserted-by":"publisher","first-page":"992","DOI":"10.21037\/atm-20-5172","volume":"8","author":"J Zhu","year":"2020","unstructured":"Zhu J, Li J, Fan Z, et al. Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy. Ann Transl Med. 2020;8:992.","journal-title":"Ann Transl Med"},{"key":"16149_CR17","doi-asserted-by":"publisher","first-page":"103376","DOI":"10.1016\/j.eclinm.2025.103376","volume":"86","author":"H Pan","year":"2025","unstructured":"Pan H, Ren Y, Zha M, et al. De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trial. EClinicalMedicine. 2025;86:103376.","journal-title":"EClinicalMedicine"},{"key":"16149_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2147\/CLEP.S97874","volume":"8","author":"AG Ording","year":"2016","unstructured":"Ording AG, Cronin-Fenton D, Ehrenstein V, et al. Challenges in translating endpoints from trials to observational cohort studies in oncology. Clin Epidemiol. 2016;8:195\u2013200.","journal-title":"Clin Epidemiol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16149-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16149-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16149-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:07:27Z","timestamp":1784952447000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16149-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16149"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16149-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated: ORCID were added to all authors.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"825"}}